Clinical Trial Update: Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update for an EGF cancer vaccine in stage IV biomarker-positive, wild-type EGFR non-small cell lung cancer; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGF Cancer Vaccine

Snippet

Sponsor: Bioven Europe | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED